Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 530-537

  Eastell, Richard ^a   Christiansen, Claus ^b   Grauer, Andreas ^c   Kutilek, Stepan ^d   Libanati, Cesar ^c   McClung, Michael R ^e   Reid, Ian R ^f   Resch, Heinrich ^g   Siris, Ethel ^h   Uebelhart, Daniel ⁱ   Wang, Andrea ^c   Weryha, Georges ^j   Cummings, Steve R ^k  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c AMGEN INC   (United States)

^d Center for Clinical and Basic Research CCBR   (Czech Republic)

^e OREGON OSTEOPOROSIS CENTER   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h University Hospital of Zurich ^*  (United States)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j CHU NANCY BRABOIS   (France)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

bone alkaline phosphtase (BALP); Bone turnover markers; C telopeptide of type I collagen (CTX); denosumab; osteoporosis; procollagen type I N terminal propeptide (PINP); tartrate resistant acid phosphatase (TRACP 5b)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; MINERAL; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RANK LIGAND; REFERENCE VALUES; STATISTICS, NONPARAMETRIC;

EID: 79951746928     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.251     Document Type: Article

References (19)

1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-765.
2. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007; 22: 1832-1841. (Pubitemid 351229299)
3. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821-831. (Pubitemid 43290920)
4. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43: 222-229.
5. Brown JP, Deal C, de Gregorio LH, et al. Effect of denosumab vs alendronate on bone turnover markers and bone mineral density changes at 12 months based on baseline bone turnover level. J Bone Miner Res. 2008; 23 (suppl 1): S80.
6. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24: 153-161.
7. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19: 1250-1258. (Pubitemid 41094365)
8. Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24: 1544-1551.
9. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD,. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18: 1051-1056. (Pubitemid 37294942)
10. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD,. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004; 19: 394-401. (Pubitemid 38787394)
11. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J,. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000; 11 (Suppl 6): S2-17.
12. Rogers A, Glover SJ, Eastell R,. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone. 2009; 45: 1044-1052.
13. Tobin J,. Estimation for relationships with limited dependent variables. Econometrica. 1958; 26: 24-36.
14. Reid I, Miller P, Brown J, et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res. 2010; 25: 2256-2265.
15. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res. 2005; 20: 2275-2282.
16. Eastell R,. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998; 338: 736-746. (Pubitemid 28115093)
17. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD,. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994; 79: 1693-1700.
18. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R,. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008; 42: 623-630.
19. Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009; 24: 389-397.